<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17146">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02883673</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-PIVOTAL-1.0</org_study_id>
    <nct_id>NCT02883673</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the InPress Device in Treating Primary Postpartum Hemorrhage</brief_title>
  <official_title>Prospective, Single Arm Pivotal Clinical Trial Designed to Assess the Safety and Performance of the InPress Device in Treating Primary Postpartum Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InPress Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InPress Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of the InPress Device in
      treating primary postpartum hemorrhage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Cessation of uterine hemorrhaging</measure>
    <time_frame>24 hrs</time_frame>
    <description>Cessation of uterine hemorrhaging, defined as average blood loss below 21 milliliters per hour (approximately 2/3 ounce/hour; 500ml/24 hours) into the vacuum canister within the first 24 hour period from start of the vacuum with placement of the InPress Device for vaginal deliveries, and average blood loss below 42 milliliters per hour, 1000 ml/ 24 hours into the vacuum canister within the first 24 hour period from start of the vacuum with placement of the InPress Device for Cesarean Section deliveries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence and severity of device-related Adverse Events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Incidence and severity of device-related Adverse Events (i.e., damage to the uterus, cervix, or vagina, infections, pyrexia, foreign body reactions) will be documented during the course of the study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InPress Device for Postpartum Hemorrhage will be administered to subjects who are diagnosed with postpartum hemorrhage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InPress Device</intervention_name>
    <description>It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult Female, 18 years of age or older

          2. Able to understand and provide informed consent to participate in the study

          3. Recent vaginal or cesarean delivery followed by postpartum hemorrhage

          4. Clinical estimate of blood loss greater than or equal to 500 ml for a vaginal or 1000
             ml for a caesarian delivery within 24 hours after birth per the World Health
             Organization guidelines for diagnosis of Primary Postpartum Hemorrhage (PPH)

          5. Hemodynamic changes that, in the opinion of the Investigator, require interventions
             beyond routine postpartum or post-delivery care

          6. Failed first-line intervention of uterotonics and uterine massage/bimanual
             compression to stop bleeding

        Exclusion Criteria:

          1. Minor (less than 18 years of age)

          2. Unable to understand and provide consent to participate in the study

          3. Delivery at a uterus size &lt; 34 weeks

          4. Cervix &lt; 3 cm dilated at the time of the decision to perform a caesarian section

          5. Loss of 1500 ml or more blood

          6. Arterial bleeding requiring surgical exploration or angiographic embolization

          7. Cases requiring immediate life-saving hysterectomy

          8. Untreated uterine anomaly

          9. Ongoing intrauterine pregnancy

         10. Retained placenta or placenta delivered incomplete unless the bulk of placenta has
             been removed, and no further placental tissue can be retrieved by a choice of manual
             and/or curettage intervention

         11. Uterine rupture or dehiscence

         12. Uterine inversion (uterine fundus not felt abdominally or visible in vagina)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rachel Acuna-Narvaez, JD</last_name>
    <phone>650-380-1191</phone>
    <email>rachel@inpresstechnologies.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz M Thornberry, JD</last_name>
      <phone>919-962-4682</phone>
      <email>liz_thornberry@unc.edu</email>
    </contact>
    <investigator>
      <last_name>Maria c Munoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Carroli G, Cuesta C, Abalos E, Gulmezoglu AM. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008 Dec;22(6):999-1012. doi: 10.1016/j.bpobgyn.2008.08.004. Epub 2008 Sep 25. Review.</citation>
    <PMID>18819848</PMID>
  </reference>
  <reference>
    <citation>Khan KS, Wojdyla D, Say L, GÃ¼lmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006 Apr 1;367(9516):1066-74. Review.</citation>
    <PMID>16581405</PMID>
  </reference>
  <reference>
    <citation>McLintock C, James AH. Obstetric hemorrhage. J Thromb Haemost. 2011 Aug;9(8):1441-51. doi: 10.1111/j.1538-7836.2011.04398.x. Review.</citation>
    <PMID>21668737</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists.. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage. Obstet Gynecol. 2006 Oct;108(4):1039-47.</citation>
    <PMID>17012482</PMID>
  </reference>
  <reference>
    <citation>Schorn MN. Measurement of blood loss: review of the literature. J Midwifery Womens Health. 2010 Jan-Feb;55(1):20-7. doi: 10.1016/j.jmwh.2009.02.014. Review.</citation>
    <PMID>20129226</PMID>
  </reference>
  <reference>
    <citation>Sapadin AN, Lebwohl MG, Teich SA, Phelps RG, DiCostanzo D, Cohen SR. Periumbilical pseudoxanthoma elasticum associated with chronic renal failure and angioid streaks--apparent regression with hemodialysis. J Am Acad Dermatol. 1998 Aug;39(2 Pt 2):338-44. Review.</citation>
    <PMID>9703148</PMID>
  </reference>
  <reference>
    <citation>Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B. Prevalence and risk factors of severe obstetric haemorrhage. BJOG. 2008 Sep;115(10):1265-72. doi: 10.1111/j.1471-0528.2008.01859.x.</citation>
    <PMID>18715412</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 3, 2016</lastchanged_date>
  <firstreceived_date>August 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postpartum Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
